OakChart

MDxHealth SA

MDXHHealthcare·Diagnostics & Research·Belgium·Nano·NASD·Nov 11 • 3:59 PM ET

0.1465+0.0072 (5.17%)
2026-11-12 04:53 CET
Market cap
13.98 USD m
Revenue, TTM
111.57 USD m
Net income, TTM
-37.34 USD m
Free cash flow, TTM
-15.77 USD m
EPS diluted, TTM
-0.73
P/E
-
Compare

Price

MDXH against its 20, 50 and 200-day averages
2050200missearnings
0.001.002.003.00163.3M326.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MDXHclose 0.1520-day 0.2050-day 0.46200-day 1.380.15

96.7% under the 52-week high of 4.49 on 11 Nov 2025. 52-week low 0.14 on 10 Nov 2026. Last 15 sessions, 56.1% high to low

Volume 0.20× normal · the line is the 50-bar volume average

Profile

MDXH
52-week range, 0% of the way up
0.144.49

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, Europe and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.

Employees364
IPONov 04, 2021
Beta0.84
ATR, 14d0.03
Rel volume0.20
Short float1.41%
Insider own31.90%
Inst own36.64%

Snapshot

6 groups

Valuation

Index-
Market Cap13.98M
Enterprise Value100.62M
Income-37.34M
Sales111.57M
Book/sh-0.59
Cash/sh0.20
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees364
IPONov 04, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S0.13
P/B-
P/C0.73
P/FCF-
EV/EBITDA-
EV/Sales0.90
Quick Ratio0.98
Current Ratio1.15
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.73
EPS next Y-0.28
EPS next Q-0.09
EPS this Y24.38%
EPS next Y44.08%
EPS next 5Y40.66%
EPS past 3/5Y37.71% 27.91%
Sales past 3/5Y42.79% 42.48%
EPS Y/Y TTM16.23%
Sales Y/Y TTM12.75%
EPS Q/Q-50.77%
Sales Q/Q2.27%
EarningsNov 12 AMC
EPS/Sales Surpr.6.93% 4.07%

Ownership

Insider Own31.90%
Insider Trans7.80%
Inst Own36.64%
Inst Trans46.78%
ROA-25.87%
ROE-2440.41%
ROIC-50.70%
Gross Margin59.15%
Oper. Margin-19.01%
Profit Margin-33.46%
SMA20-25.29%
SMA50-67.97%
SMA200-89.38%
Trades-

Technical

Shs Outstand95.42M
Shs Float64.98M
Short Float1.41%
Short Ratio0.15
Short Interest0.92M
52W High4.49 -96.74%
52W Low0.14 5.17%
Volatility12.15% 18.32%
ATR (14)0.03
RSI (14)24.33
Beta0.84
Rel Volume0.20
Avg Volume6.17M
Volume1,216,171

Performance

Perf Week-6.33%
Perf Month-77.80%
Perf Quarter-68.29%
Perf Half Y-92.49%
Perf YTD-95.90%
Perf Year-96.71%
Perf 3Y-94.80%
Perf 5Y-98.67%
Perf 10Y-
Recom2.67
Target Price1.12
Prev Close0.14
Price0.15
Change %5.17%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Oct 19, 2026DowngradeBBTIG ResearchBuy → Neutral
Oct 16, 2026DowngradeLLake StreetBuy → Hold$0.50+241.3%
Oct 16, 2026DowngradeCCraig HallumBuy → Hold
May 14, 2026DowngradeWWilliam BlairOutperform → Mkt Perform
Jul 17, 2025InitiatedCCraig HallumBuy$8+5,360.8%
Oct 31, 2024InitiatedLLake StreetBuy$7+4,678.2%
May 31, 2023InitiatedTTD CowenOutperform$7+4,678.2%
Jul 18, 2022ResumedOOppenheimerOutperform$18+12,186.7%

Peers

Mkt cap
TickerCompanyMkt cap
VCYTVeracyte Inc2.03B
MYGNMyriad Genetics Inc548.68M
OPKOpko Health Inc1.27B
CSTLCastle Biosciences Inc1.05B
XGNExagen Inc121.98M
NEONeogenomics Inc2.18B
BDSXBiodesix Inc112.22M
TECHBio-Techne Corp11.44B
IMDXInsight Molecular Diagnostics Inc78.21M
PRPOPrecipio Inc44.40M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bleichroeder LP10% OwnerSep 17 '26Proposed Sale0.701,500,0001,056,900Sep 17 05:42 PM
MVM Partners, LLCDirectorAug 13 '26Buy0.452,202,6431,000,0006,903,100Aug 17 04:05 PM

Held by

AUM
TickerCompanyAUM
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 198
  • MDxHealth Faces Credibility Test After Pre-Announced Revenue Miss And Suspended 2026 Outlook (Earnings Whispers)
  • Mdxhealth to Release Third Quarter 2026 Financial Results on November 12 (GlobeNewswire) -5.63% -9.88%
  • MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance (GlobeNewswire) -65.77%
  • MDxHealth SA (MDXH) (Q2 2026) Earnings Call Highlights: Record Sequential Growth and Strategic ... (GuruFocus.com) +74.89%
  • Mdxhealth Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Mdxhealth to Release Second Quarter 2026 Financial Results on August 13 (GlobeNewswire)
  • Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency (GlobeNewswire)
  • Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) -6.02%
  • Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial (GlobeNewswire) -6.28%
  • MDxHealth SA (MDXH) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Focus Amid ... (GuruFocus.com) -49.50%
  • Mdxhealth Reports Q1-2026 Results (GlobeNewswire)
  • Mdxhealth to Release First Quarter 2026 Financial Results on May 13 (GlobeNewswire)
  • Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 (GlobeNewswire) +5.31%
  • MDxHealth SA (MDXH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising Losses (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.092--28.745
2026Q22026-08-13-0.180-0.193-0.22027.2126.145
2026Q12026-05-13-0.190-0.145-0.17323.9030.894
2025Q42026-02-26-0.170-0.126-0.17429.5530.355
2025Q32025-11-12-0.160-0.107-0.16227.4328.135
2025Q22025-08-05-0.150-0.123-0.14926.6126.315
2025Q12025-05-14-0.190-0.130-0.18624.2923.885
2024Q42025-02-26-0.140-0.192-0.14024.7423.325
2024Q32024-11-06-0.400-0.270-0.40023.3221.515
2024Q22024-08-21-0.420-0.275-0.42322.1620.863
2024Q12024-05-01-0.310-0.299-0.31219.8318.134
2023Q42024-03-06-0.390-0.211-0.39319.4018.564
2023Q32023-11-08-0.400-0.300-0.37219.3518.215
2023Q22023-08-23-0.416-0.331-0.39316.7215.225
2023Q12023-05-15-0.500-0.413-0.50014.7013.564
2022Q42023-03-08-0.996-0.653-1.06012.9012.643

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-5.400-5.541-5.63228.4027.88
2019FY-0.530-0.381-6.88721.8625.02
2020FY-3.400-2.975-3.44518.4620.23
2021FY-2.400-2.160-2.37922.2422.90
2022FY-2.800-2.373-2.77637.1036.93
2023FY-1.660-1.274-1.66370.1969.36
2024FY-1.160-1.203-1.15990.0588.62
2025FY-0.670-0.571-0.670107.88108.9
2026FY--0.507--111.12
2027FY--0.283--125.82
2028FY--0.140--139.77
2029FY-0.010--163.5

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-0250028.7428.4729.30
2026Q3S2026-10-2850128.7428.4729.30
2026Q3S2026-10-1653128.7428.4729.30
2026Q3S2026-10-1553128.7428.4729.30
2026Q3S2026-09-2253128.7528.5029.30
2026Q3S2026-09-1253128.7428.5029.30
2026Q3S2026-08-2063128.3926.6029.30
2026Q3S2026-08-1963128.3926.6029.30
2026Q3S2026-08-1863028.4826.6029.30
2026Q3S2026-08-1463128.4826.6029.30
2026Q3S2026-08-0160128.1326.6029.05
2026Q3S2026-07-2860228.1326.6029.05
2026Q3S2026-06-0460628.1326.6029.05
2026Q3S2026-05-2450528.4327.6029.05

Estimate history

EPS, annual-2.5-5.632-6.887-3.445-2.379-2.776-1.663-1.159-0.671-0.733
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.423-0.4-0.14-0.186-0.149-0.162-0.174-0.173-0.225
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual40.50828.39711.78518.37222.23937.05470.19390.049107.875111.57
Period201720182019202020212022202320242025TTM
Sales, quarterly22.15923.31724.73924.29226.60527.43329.54527.38627.209
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual4.9955.9947.0539.06915.59716.28827.28849.49751.36551.365
Period201720182019202020212022202320242025MRQ
Shares, quarterly27.28847.28849.49749.49749.49749.49751.36551.36551.365
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue111.57107.8890.0570.1937.0522.2418.3711.7928.40
Cost of Goods Sold Incl. D&A45.5843.4339.8130.7622.7014.7113.7515.1814.59
Gross Profit65.9964.4450.2439.4414.357.534.62-3.3913.81
Selling, General and Administrative Excl. Other87.2079.8474.3366.3052.7735.5331.6833.4446.14
Research and Development9.4110.3510.556.385.245.313.072.573.10
Other Operating Expense-0.000.000.000.000.000.00-0.00
Operating Income-21.20-15.40-24.10-26.87-38.41-28.00-27.06-36.83-32.33
Interest Expense26.8312.167.955.772.741.981.540.510.08
Unusual Expense-9.356.7910.553.060.020.276.29-
Net Income Before Taxes-36.86-35.38-37.69-43.10-44.04-29.00-28.66-43.68-32.49
Income Taxes-1.58-1.860.380.000.000.000.00-0.58-0.04
Consolidated Net Income-35.28-33.52-38.07-43.10-44.04-29.00-28.66-43.10-32.45
Net Income From Continuing Operations-35.28-33.52-38.07-43.10-44.04-29.00-28.66-43.10-32.45
Net Income-37.34-33.52-38.07-43.10-44.04-29.00-28.66-43.10-32.45
EPS (Recurring)-0.73-0.54-1.01-1.38-2.64-2.38-3.42-6.18-5.63
EPS (Basic, Before Extraordinaries)-0.73-0.67-1.16-1.66-2.78-2.38-3.44-6.89-5.63
EPS (Diluted)-0.73-0.67-1.16-1.66-2.78-2.38-3.44-6.89-5.63
EBITDA-11.87-6.19-16.06-20.01-33.51-24.97-23.72-33.41-29.40
Non-Operating Income (Expense)11.171.531.150.090.171.000.21-0.05-0.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.731.661.290.500.650.920.920.620.66
Price To Sales Ratio0.191.650.861.450.005.704.575.843.96
Gross Margin59.1559.7455.7956.1838.7433.8525.17-28.7748.62
Operating Margin-19.01-14.28-26.76-38.27-103.67-125.91-147.27-312.47-113.86
Net Margin-33.46-31.07-42.28-61.40-118.86-130.41-156.01-365.72-114.27
Shares Outstanding51.3651.3649.5027.2916.2915.609.077.055.99
Market Capitalization13.9813.9864.67107.520.02180.9291.6077.58116.88

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue27.2127.3929.5527.4326.6124.2924.7423.32
Cost of Goods Sold Incl. D&A10.5812.0412.1110.8610.3610.1110.5510.37
Gross Profit16.6315.3517.4316.5816.2514.1814.1912.95
Selling, General and Administrative Excl. Other21.5922.6522.9020.0518.7218.1618.3519.05
Research and Development2.002.133.282.012.572.502.792.70
Other Operating Expense0.000.000.00--0.000.000.00
Operating Income-4.96-7.30-5.47-3.48-2.48-3.98-4.17-6.10
Interest Expense6.088.955.935.886.295.182.194.96
Unusual Expense0.00-0.000.000.000.000.000.00
Net Income Before Taxes-9.48-8.87-10.50-8.02-7.79-9.07-6.79-10.86
Income Taxes0.000.00-1.57-0.01-0.420.140.050.33
Consolidated Net Income-9.48-8.87-8.93-8.01-7.37-9.21-6.84-11.19
Net Income From Continuing Operations-9.48-8.87-8.93-8.01-7.37-9.21-6.84-11.19
Net Income-11.53-8.87-8.93-8.01-7.37-9.21-6.84-11.19
EPS (Recurring)-0.22-0.17-0.17-0.16-0.15-0.19-0.14-0.40
EPS (Basic, Before Extraordinaries)-0.22-0.17-0.17-0.16-0.15-0.19-0.14-0.40
EPS (Diluted)-0.22-0.17-0.17-0.16-0.15-0.19-0.14-0.40
EBITDA-2.71-4.91-3.03-1.22-0.21-1.73-1.97-3.96
Non-Operating Income (Expense)1.567.380.891.340.980.08-0.440.21
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.450.420.520.340.510.290.500.27
Price To Sales Ratio0.191.061.702.231.110.741.290.69
Gross Margin61.1356.0559.0160.4361.0758.3857.3555.53
Operating Margin-18.23-26.66-18.51-12.67-9.31-16.38-16.84-26.17
Net Margin-42.38-32.38-30.22-29.20-27.71-37.91-27.65-47.99
Shares Outstanding51.3651.3651.3649.5049.5049.5049.5047.29
Market Capitalization13.98113.84176.71230.16109.3938.7564.6756.76

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments29.0346.8022.3815.5058.5015.9522.0526.2016.83
Short Term Receivables14.7314.5311.279.454.833.896.7019.1319.93
Inventories6.743.872.782.331.912.321.191.811.92
Other Current Assets2.911.701.731.871.370.920.970.720.64
Total Current Assets53.4166.9038.1629.1566.6123.0930.9147.8639.32
Net Property, Plant & Equipment14.6812.989.957.895.023.712.452.072.57
Total Investments and Advances1.500.940.760.000.000.000.000.000.00
Long-Term Note Receivable--------0.00
Intangible Assets78.3776.5280.2682.093.455.067.2715.5416.64
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets147.95157.33129.13119.1475.0731.8640.6365.4858.52
Short Term Debt Incl. Current Port. of LT Debt1.901.682.121.795.283.581.220.260.36
Accounts Payable10.338.008.8110.187.465.324.964.016.09
Other Current Liabilities37.3132.988.596.313.704.134.257.216.67
Total Current Liabilities49.5342.6619.5218.2816.4313.0210.4311.4813.12
Long Term Debt84.7158.3839.1438.0110.2812.309.790.260.52
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Deferred Tax Liabilities-------0.580.62
Other Liabilities25.8141.4563.2653.541.470.690.691.040.72
Total Liabilities160.05142.49121.92109.8228.1726.0120.9013.3614.98
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-12.0914.847.219.3246.905.8519.7252.1243.55
Total Shareholders Equity-12.0914.847.219.3246.905.8519.7252.1243.55
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-12.0914.847.219.3246.905.8519.7252.1243.55
Total Liabilities & Stockholders Equity147.95157.33129.13119.1475.0731.8640.6365.4858.52
Book Value Per Share-0.240.300.260.573.010.642.808.698.72
Tangible Book Value Per Share-1.76-1.25-2.68-4.472.790.091.776.105.39
Full-Time Employees364312300258191177177187232
Price to Book Ratio-0.256.595.970.003.8615.663.932.243.88
Return on Assets-21.96-26.58-34.72-45.36-54.25-79.09-81.24-52.34-19.47
Return on Equity-2,440.41-345.31-521.70-156.70-109.96-224.16-119.99-67.84-25.52
Return on Invested Capital-46.16-51.99-92.99-93.08-50.73-157.96-146.05-61.95-27.88
Quick Ratio0.941.481.811.473.941.592.854.012.85
Current Ratio1.081.571.951.594.051.772.964.173.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-22.49-14.41-24.72-27.33-37.90-26.84-27.12-43.17-32.10
Depreciation9.589.218.046.864.913.043.333.422.94
Other Funds (Non Cash)-6.54-6.16-3.61-1.44-0.85-0.100.526.840.52
Funds from Operations-19.44-11.36-20.30-21.90-33.84-23.91-23.27-32.91-28.65
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.390.94-3.86-2.12-1.570.361.9510.30-0.29
Cash from Operating Activities-15.05-10.42-24.15-24.02-35.41-23.55-21.31-22.61-28.94
Capital Expenditures-1.05-1.16-2.16-5.02-4.16-0.90-0.54-0.07-1.35
Net Assets From Acquisitions0.000.00-0.560.00-25.000.000.000.000.00
Sale of Fixed Assets and Businesses0.780.760.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses-7.63-19.660.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-7.90-20.06-2.71-5.02-29.16-0.90-0.54-0.07-1.35
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.0040.7439.600.0068.5713.889.5842.42
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.0040.7439.600.0068.5713.889.5842.42
Proceedsfrom Stock Options0.000.0040.7439.600.0068.5713.889.5842.42
Issuance or Reduction of Debt, Net-23.9313.47-1.6623.490.002.329.52-0.36
Change in Long Term Debt----23.490.002.329.52-
Issuance of Long Term Debt----34.290.002.3210.11-
Reduction of Long Term Debt-----10.810.000.00-0.59-
Net Financing Active Other Cash Flow-7.11-8.91-1.03-0.440.000.000.000.000.00
Other Financing Activities Uses-7.11-8.91-1.03-0.440.000.000.000.000.00
Cash from Financing Activities9.3612.7051.3035.8922.1367.5115.3618.2942.07
Exchange Rate Effect-0.000.02-0.010.03-0.56-0.520.390.24-2.41
Net Change in Cash-13.60-17.7724.426.88-43.0042.55-6.10-4.159.38
Free Cash Flow-15.77-11.57-25.34-26.77-38.19-24.44-21.85-22.69-29.37
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments19.2143.1529.0332.0132.8165.67
Short Term Receivables14.9314.2614.7318.2415.7115.54
Inventories6.437.376.746.083.663.33
Other Current Assets2.463.112.911.891.601.79
Total Current Assets43.0367.8953.4158.2253.7886.33
Net Property, Plant & Equipment11.9013.8214.6816.7612.1412.53
Total Investments and Advances1.201.651.500.940.840.78
Intangible Assets75.9677.4778.3778.3673.8875.20
Other Assets0.000.000.000.000.000.00
Total Assets132.09160.83147.95154.28140.63174.83
Short Term Debt Incl. Current Port. of LT Debt1.801.751.901.961.471.55
Accounts Payable10.5712.0710.339.396.747.55
Other Current Liabilities25.0327.7637.3139.8133.0034.05
Total Current Liabilities37.4041.5849.5351.1641.2043.16
Long Term Debt104.04104.1484.7185.9482.5482.42
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities21.0535.3525.8125.4417.7743.28
Total Liabilities162.49181.06160.05162.54141.52168.87
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-30.40-20.23-12.09-8.26-0.885.97
Total Shareholders Equity-30.40-20.23-12.09-8.26-0.885.97
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-30.40-20.23-12.09-8.26-0.885.97
Total Liabilities & Stockholders Equity132.09160.83147.95154.28140.63174.83
Book Value Per Share-0.59-0.39-0.24-0.17-0.020.12
Tangible Book Value Per Share-2.07-1.90-1.76-1.75-1.51-1.40
Full-Time Employees--364---
Price to Book Ratio-0.25-13.78-21.38-260.6518.334.74
Return on Assets-25.87-19.77-21.96-20.17-25.50-26.14
Return on Equity---2,440.41-720.01--1,552.23
Return on Invested Capital-15.66-10.57-12.30-10.31-9.03-10.42
Quick Ratio0.981.460.941.021.221.92
Current Ratio1.151.631.081.141.312.00

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-7.08-7.30-5.29-2.82-2.16-4.59
Depreciation2.382.392.422.402.442.25
Other Funds (Non Cash)-0.54-1.69-1.68-2.64-1.58-0.46
Funds from Operations-5.24-6.60-4.55-3.06-1.30-2.80
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.482.852.692.33-2.75-1.30
Cash from Operating Activities-8.71-3.75-1.86-0.73-4.06-4.10
Capital Expenditures-0.04-0.69-0.04-0.28-0.40-0.48
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.00-0.010.790.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses-7.760.001.96-1.83-20.400.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-7.79-0.691.91-1.32-20.80-0.48
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.0619.406.68-6.830.7424.09
Net Financing Active Other Cash Flow-6.65-0.14-8.838.50-8.74-0.13
Other Financing Activities Uses-6.65-0.14-8.838.50-8.74-0.13
Cash from Financing Activities-7.4118.57-2.901.10-8.5523.45
Exchange Rate Effect0.00-0.00-0.00-0.000.010.01
Net Change in Cash-23.9114.12-2.86-0.95-33.3918.87
Free Cash Flow-8.75-4.11-1.90-1.01-4.45-4.58

Revenue breakdown

Consolidation, Policy2024: -49.00K 2025: 25.00K
Liquidbased2024: 17.58M 2025: 26.06M
Royalties And Other Revenues2024: 139.00K 2025: 326.00K
Tissuebased2024: 72.33M 2025: 81.49M
Belgium2024: 90.00M 2025: 107.90M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.41%0.9M65.0M6.11M
2026-10-151.84%1.2M65.0M5.60M
2026-09-302.07%1.3M65.0M5.75M
2026-09-152.34%1.5M65.0M5.94M
2026-08-312.28%1.5M67.4M5.96M
2026-08-144.01%1.5M36.3M5.94M
2026-07-312.60%1.1M41.0M823.72K
2026-07-152.33%1.0M41.0M818.71K
2026-06-300.08%0.0M41.0M745.53K
2026-06-150.26%0.1M41.0M626.81K
2026-05-291.12%0.5M41.0M512.12K
2026-05-152.22%0.9M41.0M425.60K
2026-04-300.13%0.1M40.6M159.70K
2026-04-150.05%0.0M40.6M162.56K
2026-03-310.18%0.1M40.7M143.60K
2026-03-130.10%0.0M39.2M123.83K
2026-02-270.04%0.0M39.2M126.73K
2026-02-130.06%0.0M39.2M146.63K
2026-01-300.07%0.0M39.2M153.26K
2026-01-150.07%0.0M39.2M193.14K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-30SEC
2026-10-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-16SEC
2026-10-15SCHEDULE 13D/ASEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-03SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-17SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13DSEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-08-13424B5SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-08-13SCHEDULE 13G/ASEC
2026-07-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-24SEC
2026-07-08SCHEDULE 13G/ASEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-283Initial statement of beneficial ownership of securities2026-05-18SEC
2026-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-13SEC
2026-04-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-29SEC
2026-04-133Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-133Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-133Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-081000.00K100
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Bleichroeder LP14.36%
MVM Partners, LLC9.15%
PERKINS CAPITAL MANAGEMENT INC1.35%
CITADEL ADVISORS LLC0.99%
JANE STREET GROUP, LLC0.98%
GSA CAPITAL PARTNERS LLP0.94%
RENAISSANCE TECHNOLOGIES LLC0.63%
MILLENNIUM MANAGEMENT LLC0.44%
Squarepoint Ops LLC0.39%
XTX Topco Ltd0.38%

Funds

Fund% owned
CAUSEWAY INTERNATIONAL VALUE FUND4.87%
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND1.98%
VANGUARD DEVELOPED MARKETS INDEX FUND1.32%
iShares Core MSCI EAFE ETF1.03%
Dimensional International Small Cap Value ETF0.76%
THE CONTINENTAL SMALL COMPANY SERIES0.51%
iShares MSCI EAFE ETF0.48%
INTERNATIONAL CORE EQUITY 2 PORTFOLIO0.43%
iShares MSCI EAFE Value ETF0.36%
VANGUARD EUROPEAN STOCK INDEX FUND0.32%

OakChart. MDXH. Cached 15 minutes.